-

nihao guest [ sign in / register ]
2026-11-21 19:29:29


Abbad A, Yellin T, Carre?o JM, McPartlan JS, Taluk. Self-amplifying RNA vaccines encoding chimeric and mosaic hemagglutinins confer immunity against phylogenetically diverse influenza A viruses. Cell Rep. 2026 Nov 6:118244
submited by kickingbird at Nov, 9, 2026 9:8 AM from Cell Rep. 2026 Nov 6:118244

Seasonal influenza vaccines require annual reformulation due to antigenic drift and provide suboptimal protection. Here, we evaluate self-amplifying mRNA (samRNA) vaccines encoding chimeric (cHA) and mosaic (mHA) hemagglutinins representing influenza A virus HA phylogenetic groups 1 and 2. Following prime-boost immunization, group 1 cHA vaccines (cH8/1-cH5/1) elicit broad cross-reactive antibodies and confer complete protection against diverse H1N1 strains covering decades of antigenic drift. Group 2 vaccines (cH4/3-cH15/3 and mH10/3-mH14/3) provide comparable breadth against multiple H3N2 strains and heterosubtypic H7N9 challenge, with cHA samRNA showing superior cross-group protection. Protection is associated with Fc-mediated effector functions and CD4+ T cell responses, with minimal hemagglutination inhibition and neutralizing titers. Passive serum transfer confirms antibody-mediated protection independent of cellular immunity. Protective immunity is maintained at doses as low as 0.4 μg, demonstrating the dose-sparing advantage of the samRNA platform. These results support samRNA-delivered cHA and mHA antigens as promising candidates for broadly protective influenza vaccines.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


  

Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
Copyright ©www.flu.org.cn. 2004-2026. All Rights Reserved. Powered by FIC 4.0.1
  Email:webmaster@flu.org.cn